Details of the Drug

General Information of Drug (ID: DM5TVS3)

Drug Name
Vinblastine
Synonyms
Nincaluicolflastine; Rozevin; VLB; Vinblastin; Vinblastina; Vinblastinum; Vincaleucoblastin; Vincaleucoblastine; Vincaleukoblastine; Vincoblastine; Vinblastina [DCIT]; VR-8; Vinblastina (TN); Vinblastine (INN); Vinblastine [INN:BAN]; Vinblastinum [INN-Latin]; NDC 0002-1452-01; (2ALPHA,2'BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE; (2xi,3beta,4'beta,19xi)-vincaleukoblastine; 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 811
Topological Polar Surface Area (xlogp) 3.7
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 12
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.1 mL/min/kg [4]
Elimination
0.5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 19 hours [4]
Metabolism
The drug is metabolized via the hepatic [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.14% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 28 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL [3]
Chemical Identifiers
Formula
C46H58N4O9
IUPAC Name
methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
Canonical SMILES
CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
InChI
InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1
InChIKey
JXLYSJRDGCGARV-CFWMRBGOSA-N
Cross-matching ID
PubChem CID
13342
CAS Number
865-21-4
DrugBank ID
DB00570
TTD ID
D0W9MM
VARIDT ID
DR00308
INTEDE ID
DR1689

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin beta-2 chain (TUBB2) TTJ2PTI TBB2A_HUMAN Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance protein 3 (ABCB4) DTZRMK5 MDR3_HUMAN Substrate [7]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [8]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [9]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [13]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vinblastine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased metabolism of Vinblastine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [78]
Armodafinil DMGB035 Minor Increased metabolism of Vinblastine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [79]
LEE011 DMMX75K Moderate Decreased metabolism of Vinblastine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [80]
Etoposide DMNH3PG Minor Decreased metabolism of Vinblastine caused by Etoposide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [81]
Doxorubicin DMVP5YE Minor Decreased metabolism of Vinblastine caused by Doxorubicin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [81]
Coadministration of a Drug Treating the Disease Different from Vinblastine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Vinblastine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [82]
Midostaurin DMI6E0R Moderate Decreased clearance of Vinblastine due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [83]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Vinblastine due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [78]
Siltuximab DMGEATB Moderate Additive myelosuppressive effects by the combination of Vinblastine and Siltuximab. Anemia [3A00-3A9Z] [83]
Dronedarone DMA8FS5 Moderate Decreased clearance of Vinblastine due to the transporter inhibition by Dronedarone. Angina pectoris [BA40] [84]
Voriconazole DMAOL2S Major Decreased clearance of Vinblastine due to the transporter inhibition by Voriconazole. Aspergillosis [1F20] [85]
Posaconazole DMUL5EW Major Decreased metabolism of Vinblastine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [85]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Vinblastine and Roflumilast. Asthma [CA23] [83]
Ofloxacin DM0VQN3 Minor Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [86]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Vinblastine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [87]
Clarithromycin DM4M1SG Major Decreased clearance of Vinblastine due to the transporter inhibition by Clarithromycin. Bacterial infection [1A00-1C4Z] [85]
Trovafloxacin DM6AN32 Minor Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [86]
Sparfloxacin DMB4HCT Minor Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [86]
Gemifloxacin DMHT34O Minor Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [86]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [86]
ABT-492 DMJFD2I Minor Decreased absorption of Vinblastine due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [86]
Levofloxacin DMS60RB Minor Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [86]
Troleandomycin DMUZNIG Major Decreased clearance of Vinblastine due to the transporter inhibition by Troleandomycin. Bacterial infection [1A00-1C4Z] [85]
Lomefloxacin DMVRH9C Minor Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [86]
Telithromycin DMZ4P3A Major Decreased clearance of Vinblastine due to the transporter inhibition by Telithromycin. Bacterial infection [1A00-1C4Z] [85]
Erdafitinib DMI782S Moderate Decreased clearance of Vinblastine due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [88]
Lomustine DMMWSUL Minor Decreased metabolism of Vinblastine caused by Lomustine mediated inhibition of CYP450 enzyme. Brain cancer [2A00] [81]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Vinblastine caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [89]
Tucatinib DMBESUA Major Decreased clearance of Vinblastine due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [85]
Palbociclib DMD7L94 Moderate Decreased metabolism of Vinblastine caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [90]
Capecitabine DMTS85L Minor Decreased metabolism of Vinblastine caused by Capecitabine mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [81]
Mifepristone DMGZQEF Moderate Decreased metabolism of Vinblastine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [78]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Vinblastine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [91]
MK-8228 DMOB58Q Moderate Decreased metabolism of Vinblastine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [92]
Aprepitant DM053KT Moderate Decreased metabolism of Vinblastine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [93]
Nefazodone DM4ZS8M Major Decreased metabolism of Vinblastine caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [85]
Primidone DM0WX6I Moderate Increased metabolism of Vinblastine caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [94]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Vinblastine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [95]
Cenobamate DMGOVHA Moderate Increased metabolism of Vinblastine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [96]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Vinblastine caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [97]
Rufinamide DMWE60C Moderate Increased metabolism of Vinblastine caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [83]
Phenobarbital DMXZOCG Moderate Increased metabolism of Vinblastine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [94]
Tazemetostat DMWP1BH Moderate Increased metabolism of Vinblastine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [98]
Itraconazole DMCR1MV Major Decreased clearance of Vinblastine due to the transporter inhibition by Itraconazole. Fungal infection [1F29-1F2F] [85]
Miconazole DMPMYE8 Moderate Decreased metabolism of Vinblastine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [99]
Ketoconazole DMPZI3Q Major Decreased metabolism of Vinblastine caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [85]
Boceprevir DMBSHMF Major Decreased clearance of Vinblastine due to the transporter inhibition by Boceprevir. Hepatitis virus infection [1E50-1E51] [85]
Telaprevir DMMRV29 Major Decreased metabolism of Vinblastine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [85]
Rifampin DMA8J1G Moderate Accelerated clearance of Vinblastine due to the transporter induction by Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [94]
Rifapentine DMCHV4I Moderate Accelerated clearance of Vinblastine due to the transporter induction by Rifapentine. HIV-infected patients with tuberculosis [1B10-1B14] [94]
Delavirdine DM3NF5G Major Decreased metabolism of Vinblastine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Vinblastine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Cobicistat DM6L4H2 Major Decreased clearance of Vinblastine due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [85]
Efavirenz DMC0GSJ Moderate Increased metabolism of Vinblastine caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [100]
Saquinavir DMG814N Major Decreased metabolism of Vinblastine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Amprenavir DMLMXE0 Major Decreased metabolism of Vinblastine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Darunavir DMN3GCH Moderate Decreased metabolism of Vinblastine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [101]
Atazanavir DMSYRBX Major Decreased metabolism of Vinblastine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Vinblastine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [102]
BMS-201038 DMQTAGO Moderate Decreased clearance of Vinblastine due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [103]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Vinblastine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [78]
Conivaptan DM1V329 Major Decreased metabolism of Vinblastine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [85]
Tolvaptan DMIWFRL Moderate Decreased clearance of Vinblastine due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [78]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Vinblastine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [104]
Amobarbital DM0GQ8N Moderate Increased metabolism of Vinblastine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [94]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Vinblastine caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [83]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Vinblastine and Denosumab. Low bone mass disorder [FB83] [105]
Crizotinib DM4F29C Moderate Decreased metabolism of Vinblastine caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [106]
Brigatinib DM7W94S Moderate Increased metabolism of Vinblastine caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [107]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Vinblastine and Porfimer Sodium. Lung cancer [2C25] [108]
Ceritinib DMB920Z Major Decreased metabolism of Vinblastine caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [85]
PF-06463922 DMKM7EW Moderate Increased metabolism of Vinblastine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [109]
Osimertinib DMRJLAT Moderate Decreased metabolism of Vinblastine caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [83]
Capmatinib DMYCXKL Moderate Decreased clearance of Vinblastine due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [110]
Selpercatinib DMZR15V Moderate Decreased metabolism of Vinblastine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [83]
Idelalisib DM602WT Major Decreased metabolism of Vinblastine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [85]
IPI-145 DMWA24P Moderate Decreased metabolism of Vinblastine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [111]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Vinblastine caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [112]
LGX818 DMNQXV8 Moderate Increased metabolism of Vinblastine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [113]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Vinblastine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [83]
Lasmiditan DMXLVDT Moderate Decreased clearance of Vinblastine due to the transporter inhibition by Lasmiditan. Migraine [8A80] [114]
Exjade DMHPRWG Moderate Decreased metabolism of Vinblastine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [115]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Vinblastine and Thalidomide. Multiple myeloma [2A83] [116]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Vinblastine and Tecfidera. Multiple sclerosis [8A40] [117]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Vinblastine and Siponimod. Multiple sclerosis [8A40] [78]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Vinblastine and Fingolimod. Multiple sclerosis [8A40] [118]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Vinblastine and Ocrelizumab. Multiple sclerosis [8A40] [119]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Vinblastine and Ozanimod. Multiple sclerosis [8A40] [83]
Rifabutin DM1YBHK Moderate Increased metabolism of Vinblastine caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [94]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Vinblastine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [83]
Nilotinib DM7HXWT Moderate Decreased clearance of Vinblastine due to the transporter inhibition by Nilotinib. Myeloproliferative neoplasm [2A20] [120]
Imatinib DM7RJXL Moderate Decreased metabolism of Vinblastine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [121]
Dasatinib DMJV2EK Moderate Decreased metabolism of Vinblastine caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [122]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Vinblastine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [123]
Modafinil DMYILBE Minor Increased metabolism of Vinblastine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [79]
Rolapitant DM8XP26 Moderate Decreased clearance of Vinblastine due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [124]
Entrectinib DMMPTLH Moderate Decreased metabolism of Vinblastine caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [125]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Vinblastine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [126]
Abametapir DM2RX0I Moderate Decreased metabolism of Vinblastine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [127]
Lefamulin DME6G97 Moderate Decreased metabolism of Vinblastine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [128]
Lonafarnib DMGM2Z6 Major Decreased clearance of Vinblastine due to the transporter inhibition by Lonafarnib. Premature ageing appearance [LD2B] [85]
Enzalutamide DMGL19D Moderate Accelerated clearance of Vinblastine due to the transporter induction by Enzalutamide. Prostate cancer [2C82] [129]
Ustekinumab DMHTYK3 Moderate Additive myelosuppressive effects by the combination of Vinblastine and Ustekinumab. Psoriasis [EA90] [83]
Tildrakizumab DMLW9HG Moderate Additive immunosuppressive effects by the combination of Vinblastine and Tildrakizumab. Psoriasis [EA90] [83]
Risankizumab DMM32GT Moderate Additive immunosuppressive effects by the combination of Vinblastine and Risankizumab. Psoriasis [EA90] [83]
Ixekizumab DMXW92T Moderate Additive immunosuppressive effects by the combination of Vinblastine and Ixekizumab. Psoriasis [EA90] [83]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Vinblastine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [130]
Gatifloxacin DMSL679 Minor Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [86]
Tocilizumab DM7J6OR Moderate Additive myelosuppressive effects by the combination of Vinblastine and Tocilizumab. Rheumatoid arthritis [FA20] [83]
Canakinumab DM8HLO5 Moderate Additive myelosuppressive effects by the combination of Vinblastine and Canakinumab. Rheumatoid arthritis [FA20] [83]
Rilonacept DMGLUQS Moderate Additive myelosuppressive effects by the combination of Vinblastine and Rilonacept. Rheumatoid arthritis [FA20] [83]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Vinblastine and Golimumab. Rheumatoid arthritis [FA20] [131]
Dexamethasone DMMWZET Moderate Increased metabolism of Vinblastine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [94]
Sarilumab DMOGNXY Moderate Additive immunosuppressive effects by the combination of Vinblastine and Sarilumab. Rheumatoid arthritis [FA20] [83]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Vinblastine and Leflunomide. Rheumatoid arthritis [FA20] [102]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Vinblastine when combined with Anthrax vaccine. Sepsis [1G40-1G41] [132]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Vinblastine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [83]
Pitolisant DM8RFNJ Moderate Increased metabolism of Vinblastine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [83]
Fostamatinib DM6AUHV Moderate Decreased clearance of Vinblastine due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [133]
Brilinta DMBR01X Moderate Decreased metabolism of Vinblastine caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [83]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Vinblastine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [130]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Vinblastine and Azathioprine. Transplant rejection [NE84] [78]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Vinblastine and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [130]
Cinoxacin DM4EWNS Minor Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [86]
Nalidixic acid DMRM0JV Minor Decreased absorption of Vinblastine due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [86]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Vinblastine and Ganciclovir. Virus infection [1A24-1D9Z] [78]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Vinblastine and Valganciclovir. Virus infection [1A24-1D9Z] [78]
⏷ Show the Full List of 122 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6851).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20.
7 MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9.
8 Severe hypokalemia due to a possible drug-drug interaction between vinblastine and antiretrovirals in a HIV-infected patient with Hodgkin's lymphoma. Int J STD AIDS. 2017 Oct;28(12):1259-1262.
9 Development and characterization of a recombinant Madin-Darby canine kidney cell line that expresses rat multidrug resistance-associated protein 1 (rMRP1). AAPS PharmSci. 2004 Mar 9;6(1):E8.
10 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
11 Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84.
12 Induction of CYP3A4 by vinblastine: role of the nuclear receptor NR1I2. Ann Pharmacother. 2010 Nov;44(11):1709-17.
13 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
14 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
25 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
26 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
27 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
28 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
29 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
30 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
31 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
32 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
33 Drug Interactions Flockhart Table
34 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
35 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
36 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
37 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
38 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
39 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
40 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
41 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
42 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
43 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
44 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
45 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
46 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
47 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
48 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
49 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
50 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
51 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
52 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
53 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
54 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
55 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
56 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
57 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
58 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
59 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
60 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
61 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
62 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
63 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
64 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
65 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
66 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
67 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
68 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
69 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
70 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
71 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
72 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
73 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
74 Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45.
75 Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
76 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5.
77 Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006 Sep 21;49(19):5664-70.
78 Cerner Multum, Inc. "Australian Product Information.".
79 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
80 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
81 Zhou-Pan XR, Seree E, Zhou XJ, et al "Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions." Cancer Res 53 (1993): 5121-6. [PMID: 8221648]
82 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
83 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
84 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
85 Antoniou T, Tseng AL "Interactions between antiretrovirals and antineoplastic drug therapy." Clin Pharmacokinet 44 (2005): 111-145. [PMID: 15656694]
86 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
87 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
88 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
89 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
90 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
91 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
92 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
93 Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
94 Product Information. Marqibo (vinCRIStine liposome). Talon Therapeutics Inc, South San Francisco,, CA.
95 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
96 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
97 Bollini P, Riva R, Albani F, Ida et al "Decreased phenytoin level during antineoplastic therapy: a case report." Epilepsia 24 (1983): 75-8. [PMID: 6822234]
98 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
99 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
100 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
101 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
102 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
103 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
104 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
105 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
106 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
107 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
108 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
109 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
110 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
111 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
112 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
113 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
114 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
115 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
116 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
117 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
118 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
119 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
120 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
121 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
122 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
123 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
124 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
125 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
126 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
127 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
128 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
129 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
130 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
131 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
132 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
133 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.